α-cd8 ab clone 53-6.7 antibody  (Bio X Cell)

Journal: iScience

Article Title: TAMs-specific ARF1 inhibition reprograms glioma microenvironment and enhances the therapeutic effect of oncolytic adenovirus

doi: 10.1016/j.isci.2025.112696

Figure Lengend Snippet: TAMs specific suppression of ARF1 expression reprograms TAMs (A) Cartoon shows the structure of oncolytic adenovirus carrying macrophage-specific ARF1 inhibition cassette. (B and C) RAW264.7 cell line was infected by oncolytic adenovirus carrying a macrophage-specific ARF1 knockdown element or control virus, the expression of ARF1 (B) and inflammatory genes (C) was analyzed by RT-PCR. (D–F) GL261-OVA-luci cell line was inoculated into the right brain of C57BL6 mice, seven days after cell inoculation, indicated virus or PBS was injected intratumorally every two days for three times. (D and E) The growth of tumor. The size of tumor in every mouse was detected at 21 days after tumor cell inoculation using an in vivo imaging system. (F) The survival of mice with different treatments was analyzed. (G–J) Mice were sacrificed on day 15 post the last treatment, immune cells were isolated, counted and analyzed by flow cytometry. Tumoral tissues were embedded in OCT, sectioned and analyzed by immunofluorescence staining. (G) TAM-specific knockdown of ARF1 increases the infiltration of immune cells. (H and I) TAM-specific knockdown of ARF1 reprograms TAMs into a pro-inflammatory state. Infection of TAMs was verified by immunostaining (H), Scale bars: 100 μm. F4/80+GFP+ cells were sorted from the total immune cells as TAMs, and the expression of inflammatory genes was analyzed by RT-PCR (I). (J) TAMs specific inhibition of ARF1 increases the percentage of CD8 + T cells in tumor infiltrated immune cells. (K) TAMs-specific inhibition of ARF1 enhances tumor antigen-specific immune response. Tumor-infiltrating CD8 + T cells were isolated and co-cultured with dendritic cells pre-loaded with OVA peptides, the secretion of IFN-γ was analyzed by ELISA. All results are presented as means ± SD.

Article Snippet: Rat anti Mouse CD8 α Monoclonal Antibody (53-6.7) , Thermo Fisher (America) , Cat#A15386; RRID: AB_2534400.

Techniques: Expressing, Inhibition, Infection, Knockdown, Control, Virus, Reverse Transcription Polymerase Chain Reaction, Injection, In Vivo Imaging, Isolation, Flow Cytometry, Immunofluorescence, Staining, Immunostaining, Cell Culture, Enzyme-linked Immunosorbent Assay

Journal: Discover Oncology

Article Title: Inhibiting glycolysis facilitated checkpoint blockade therapy for triple-negative breast cancer

doi: 10.1007/s12672-025-02320-w

Figure Lengend Snippet: Knockdown of HK2 suppresses MDSC development in the tumor microenvironment. A , B MDSCs derived from bone marrow cells co-cultured with G-CSF or supernatants from scrambled and shHK2 4T1 cells were analyzed by flow cytometry (n = 3/group). Mice (n = 9/group) were implanted with 4T1 or shHK2 4T1 cells. C Tumor images from scrambled and shHK2 4T1-bearing mice after 23 days (n = 9/group). D Tumor growth curves of indicated groups (n = 9/group). E Survival analysis of mice bearing scrambled and shHK2 4T1 tumors. F G-CSF expression in tumor tissues analyzed by western blotting. G , H MDSCs in tumor tissues of mice bearing scrambled and shHK2 4T1 cells, shown as percentages of Gr1+CD11b+cells within CD45+ cells by flow cytometry. Significance: *p < 0.05, **p < 0.01, ***p < 0.001. Data presented as mean ± SD

Article Snippet: The single-cell suspensions were stained in the dark at 4 °C for at least 30 min in FACS buffer with fluorescence-conjugated antibodies against CD45, CD3, CD8, TNF-α, IFN-γ, Gr-1, Ly6G, and CD11b (BD, USA).

Techniques: Knockdown, Derivative Assay, Cell Culture, Flow Cytometry, Expressing, Western Blot

Journal: Discover Oncology

Article Title: Inhibiting glycolysis facilitated checkpoint blockade therapy for triple-negative breast cancer

doi: 10.1007/s12672-025-02320-w

Figure Lengend Snippet: HK2 inhibition augments immunotherapeutic efficacy of PD-L1 antibody in triple-negative breast cancer. 4T1-bearing mice were treated with control, 3-BrPA, PD-L1 antibody, or combination therapy (n = 5/group). A Tumor images of 4T1 breast cancer mice. B Tumor growth curves for each group; tumor volume data are shown as mean ± SD (n = 5/group). C Survival analysis of mice treated with PD-L1 antibody, 3-BrPA, or their combination (n = 5/group). D , E Flow cytometry dot plots showing Gr1+ CD11b+ cells within CD45+ cells in tumor tissues from treated mice; percentages are given (n = 5/group). F , G Scatter plots of CD8+ T lymphocytes within CD45 + cells for each treatment group (n = 5/group). H – J Flow cytometry dot plots and percentages of TNF-α and IFN-γ expression in CD8+ T cells in 4T1 tumor tissue (n = 5/group). Significance: ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001. Error bars indicate mean ± SD

Article Snippet: The single-cell suspensions were stained in the dark at 4 °C for at least 30 min in FACS buffer with fluorescence-conjugated antibodies against CD45, CD3, CD8, TNF-α, IFN-γ, Gr-1, Ly6G, and CD11b (BD, USA).

Techniques: Inhibition, Control, Flow Cytometry, Expressing

Journal: The EMBO Journal

Article Title: T-cell-derived IFN-γ suppresses T follicular helper cell differentiation and antibody responses

doi: 10.1038/s44318-025-00414-3

Figure Lengend Snippet: Reagents and tools table

Article Snippet: InVivoMab α-CD8 depleting antibody , BioXcell , Clone YTS 169.4 #BE0117.

Techniques: Transgenic Assay, Mouse Assay, Recombinant, Blocking Assay, Control, Staining, Sequencing, Expressing, Derivative Assay, Lysis, Software, Cell Isolation, Microscopy, Real-time Polymerase Chain Reaction